arrow
W

Warren Fingrut

American Society for Transplantation and Cellular Therapy
H指数:14
被引数:730

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

在高风险急性髓系白血病和骨髓增生异常性肿瘤中,使用允许性的HLA-DPB1错配和移植后环磷酰胺可降低复发率。

Leukemia
IF13.4
2026-03-090
OAAI
Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time

了解血液学健康的社会决定因素的影响: 跨期刊和随时间变化趋势的范围审查

2026-01-290
OAAI
Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis

建立供者年龄和类型权衡模型,以在采用移植后环磷酰胺预防措施的同种异基因造血细胞移植中进行个性化选择

Leukemia
IF13.4
2026-01-120
PRE
Establishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for the Duffy Null Population

建立 Duffy 零人群中绝对中性粒细胞计数和白细胞的参考区间

2026-01-010
OAAI
Organ and tissue donation and transplantation in people who identify as Two-Spirit, gay, bisexual, transgender, queer, intersex, and more: a Canada-wide cross-sectional community survey
2025-12-220
OAAI
Insurance Barriers to High-Cost Anti-Infective Medications Post Allogeneic Hematopoietic Cell Transplant

异基因造血细胞移植后高价抗感染药物的医疗险障碍

2025-07-090
PRE
Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

供者年龄和供-受者性别不匹配对HLA匹配的亲属与非亲属供者造血细胞移植结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

供者年龄较轻的半相合造血干细胞移植疗效改善

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

大剂量分次马利兰、氟达拉滨、克拉屈滨、替莫唑胺和维奈克拉(Cladillac)预处理方案用于极高危AML/MDS:一项Ⅱ期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Genetic Findings of Potential Donor Origin following Hematopoietic Cell Transplantation: Recommendations on Donor Disclosure and Genetic Testing from the World Marrow Donor Association
2024-02-013
OAAI